Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Cash from Financing Activities: 2010-2024

Historic Cash from Financing Activities for Capricor Therapeutics (CAPR) over the last 15 years, with Dec 2024 value amounting to $152.8 million.

  • Capricor Therapeutics' Cash from Financing Activities fell 99.99% to $6,950 in Q3 2025 from the same period last year, while for Sep 2025 it was $81.2 million, marking a year-over-year decrease of 14.43%. This contributed to the annual value of $152.8 million for FY2024, which is 497.23% up from last year.
  • According to the latest figures from FY2024, Capricor Therapeutics' Cash from Financing Activities is $152.8 million, which was up 497.23% from $25.6 million recorded in FY2023.
  • Capricor Therapeutics' 5-year Cash from Financing Activities high stood at $152.8 million for FY2024, and its period low was $4.9 million during FY2022.
  • For the 3-year period, Capricor Therapeutics' Cash from Financing Activities averaged around $61.1 million, with its median value being $25.6 million (2023).
  • As far as peak fluctuations go, Capricor Therapeutics' Cash from Financing Activities crashed by 75.90% in 2022, and later skyrocketed by 497.23% in 2024.
  • Over the past 5 years, Capricor Therapeutics' Cash from Financing Activities (Yearly) stood at $33.4 million in 2020, then slumped by 39.41% to $20.2 million in 2021, then tumbled by 75.90% to $4.9 million in 2022, then soared by 424.84% to $25.6 million in 2023, then spiked by 497.23% to $152.8 million in 2024.